Evidence mapPaperPMID 37051319Full record

ReviewInternational journal of nephrology and renovascular disease2023

Chronic Kidney Disease Management in the Middle East and Africa: Concerns, Challenges, and Novel Approaches.

Saeed Al-Ghamdi, Ali Abu-Alfa, Turki Alotaibi, Ali AlSaaidi, Abdulkareem AlSuwaida, Mustafa Arici, Tevfik Ecder, Ahmed F El Koraie, Mohamed Ghnaimat, Mohamed H Hafez and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in International journal of nephrology and renovascular disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 3 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 11 institutions in 8 countries.

Saeed Al-GhamdiDepartment of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom Saudi of Arabia.
Ali Abu-AlfaDepartment of Nephrology and Hypertension, American University of Beirut, Beirut, Lebanon.
Turki AlotaibiDepartment of Transplant Nephrology, Hamed Al-Essa Organ Transplant Center, Kuwait City, Kuwait.
Ali AlSaaidiDepartment of Nephrology, College of Medicine, University of Baghdad, Nephrology and Transplantation Center, Medical City Complex, Baghdad, Iraq.
Abdulkareem AlSuwaidaDepartment of Medicine, King Saud University, Riyadh, Saudi Arabia.
Mustafa AriciDepartment of Nephrology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Tevfik EcderDepartment of Nephrology, Demiroglu Bilim University Faculty of Medicine, Istanbul, Turkey.
Ahmed F El KoraieDepartment of Internal Medicine and Nephrology, Alexandria Faculty of Medicine, Alexandria, Egypt.
Mohamed GhnaimatDepartment of Nephrology Specialty Hospital, Amman, Jordan.
Mohamed H HafezDepartment of Nephrology and Medicine, Cairo University, Cairo, Egypt.
Mohamed HassanDepartment of Medical Affairs, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.
Tarik SqalliDepartment of Nephrology, Moroccan Society of Nephrology, Casablanca, Morocco.
Alexandria University · EGAmerican University of Beirut · LBBaghdad Medical City · IQCairo University · EGHacettepe University · TRIstanbul Bilim University · TRKing Abdulaziz University · SAKing Saud University · SAKuwait Cancer Control Center · KWShaikh Khalifa Medical City · AESpecialty Hospital, Jordan · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The burden of chronic kidney disease (CKD) and other comorbidities, such as hypertension and diabetes, which increase the risk of developing CKD, is on the rise in the Middle East and Africa. The Middle East and Africa CKD (MEA-CKD) steering committee, comprising eminent healthcare specialists from the Middle East and Africa, was formed to identify and propose steps to address the gaps in the management of CKD in these regions. The current article lists the MEA-CKD steering committee meeting outcomes and evaluates the available evidence supporting the role of novel therapeutic options for patients with CKD. The need of the hour is to address the gaps in awareness and screening, early diagnosis, along with referral and management of patients at risk. Measures to bring about appropriate changes in healthcare policies to ensure access to all benefit-proven protective therapies, including novel ones, at community levels are also vital for reducing the overall burden of CKD on the healthcare system as well as governing bodies, especially in developing countries of the Middle East and Africa.

Indexed as

chronic kidney diseaseCKD concernsCKD managementCKD management gapsMiddle East and Africanovel therapies

Identifiers

PMID37051319
PMCPMC10084934
OpenAlexW4362638898

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.